making $
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$INAB keep an eye out!
$HOLO Warrants $HOLOW on sale by 90%!!! $.10!!!
$HOLO Warrants $HOLOW on sale by 90%!!! $.10!!!
$INAB $1.79 up 50% this week... Next 10 bagger on Phase 3 news!!
$INAB $1.79 up 50% this week... Next 10 bagger on Phase 3 news!!
$AAGR flying!! $1.13 ten bagger incoming!
$AAGR $1.13 ten bagger incoming!
$YAHOY - Thai Whats app on sale at $6!
$YAHOY - Thai Whats app on sale at $6!
$SAN $4.23 Santander Bank on sale and going parabolic! PE is 4!
$SAN $4.23 Santander Bank on sale and going parabolic! PE is 4!
$INAB is the next 10 bagger $.84, look at the setup!!!
$INAB is the next 10 bagger $.84, look at the setup!!!
$BBAR next 5 bagger! Argentina stocks flying!!! $5.6 heading to $25!
$BBAR next 5 bagger! Argentina stocks flying!!! $5.6 heading to $25!
$BBAR next 5 bagger! Argentina stocks flying!!! $5.6 heading to $25!
$DOGZ huge bids stacking! 10 bagger coming here!
$DOGZ huge bids stacking! 10 bagger coming here!
DOGZ baby! Double bottom - 10 bag coming!
DOGZ baby! Double bottom - 10 bag coming!
$DOGZ double bottom on the monthly, this is the next 10 bagger!
$DOGZ about to run
$DOGZ about to run
$DOGZ .73 up 11%! Could be a ten bagger here, double bottom formed on the monthly! This did 10x before!
$DOGZ .73 up 11%! Could be a ten bagger here, double bottom formed on the monthly! This did 10x before!
INAB on sale
INAB on sale, will pop soon
$INAB $2.84 now! headed to $20 on major cancer developments! Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors.
$INAB $2.84 now! headed to $20 on major cancer developments! Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors.
$INAB $2.84 now! headed to $20 on major cancer developments! Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors.
$INAB $2.62 headed to $20 on major cancer developments! Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors.
$INAB $2.62 headed to $20 on major cancer developments! Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors.
Headed to $20 on cancer developments
TUP $8 Major earnings beat, up 20% premarket, no resistance, headed to $20!!!
TUP $8 Major earnings beat, up 20% premarket, no resistance, headed to $20!!!
New LABU Analysis
New WEBL Analysis
New DFEN Analysis!
New SOXL Analysis!
TUP $7.30, technical breakout!